First in human clinical trial to evaluate the safety, tolerability and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer
Phase 1
Recruiting
- Conditions
- Progressive metastatic solid cancer after failure of established treatment optionsMedDRA version: 20.0Level: LLTClassification code: 10031295Term: Osteosarcoma NOS Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10006188Term: Breast cancer female NOS Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10024631Term: Liposarcoma NOS Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10042866Term: Synovial sarcoma NOS Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10010029Term: Colorectal cancer NOS Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10024193Term: Leiomyosarcoma NOS Class: 10029104Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Therapeutic area: Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]
- Registration Number
- CTIS2022-503084-15-00
- Lead Sponsor
- Deutsches Krebsforschungszentrum (DKFZ)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 77
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary end point(s): ;Main Objective: ;Secondary Objective:
- Secondary Outcome Measures
Name Time Method